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1. Introduction
DNA damage appears to be a fundamental problem for life. In this chapter we review evi‐
dence indicating that DNA damages are a major primary cause of cancer. DNA damages
give rise to mutations and epimutations that, by a process of natural selection, can cause
progression to cancer. First, we describe the distinguishing characteristics of DNA damage,
mutation and epimutation.
DNA damage is a change in the basic structure of DNA that is not itself replicated when the
DNA is replicated. A DNA damage can be a chemical addition or disruption to a base of
DNA (creating an abnormal nucleotide or nucleotide fragment) or a break in one or both
chains of the DNA strands. When DNA carrying a damaged base is replicated, an incorrect
base can often be inserted opposite the site of the damaged base in the complementary
strand, and this can become a mutation in the next round of replication. Also DNA double-
strand breaks may be repaired by an inaccurate repair process leading to mutations. In addi‐
tion, a double strand break can cause rearrangements of the chromosome structure (possibly
disrupting a gene, or causing a gene to come under abnormal regulatory control), and, if
such a change can be passed to successive cell generations, it is also a form of mutation. Mu‐
tations, however, can be avoided if accurate DNA repair systems recognize DNA damages
as abnormal structures, and repair the damages prior to replication. As illustrated in Figure
1, when DNA damages occur, DNA repair is a crucial protective process blocking entry of
cells into carcinogenesis.
We note that DNA damages occur in both replicating, proliferative cells (e.g. those forming
the internal lining of the colon or blood forming “hematopoietic” cells), and in differentiat‐
ed, non-dividing cells (e.g. neurons in the brain or myocytes in muscle). Cancers occur pri‐
marily in proliferative tissues. If DNA damages in proliferating cells are not repaired due to
© 2013 Bernstein et al.; licensee InTech. This is an open access article distributed under the terms of the
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inadequate expression of a DNA repair gene, this increases the risk of cancer. In contrast,
when DNA damages occur in non-proliferating cells and are not repaired due to inadequate
expression of a DNA repair gene, the damages can accumulate and cause premature aging.
As examples, deficiencies in DNA repair genes ERCC1 or XPF [1] or in WRN [2, 3] cause
both increased risk of cancer as well as premature aging. In Figure 1, DNA repair is indicat‐
ed as a crucial process impeding both cancer and premature aging.
Figure 1. The roles of DNA damage and DNA repair in cancer and aging.
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A mutation is a change in the DNA sequence in which normal base pairs are substituted,
added, deleted or rearranged. The DNA containing a mutation still consists of a sequence of
standard base pairs, and the altered DNA sequence can be copied when the DNA is replicat‐
ed. A mutation can prevent a gene from carrying out its function, or it can cause a gene to be
translated into a protein that functions abnormally. Mutations can activate oncogenes, inac‐
tivate tumor suppressor genes or cause genomic instability in replicating cells, and an as‐
semblage of such mutations, together in the same cell, can lead to cancer. Cancers usually
arise from an assemblage of mutations conferring a selective advantage that leads to clonal
expansion (Figure 1). Colon cancers, for example, have an average of 15 “driver” mutations
(mutations occurring repeatedly in different colon cancers) and about 75 “passenger” muta‐
tions (mutations occurring infrequently in colon cancers) [4, 5]. Colon cancers also were
found to have an average of 9 duplications or deletions of chromosome segments [6] or,
more recently, 17 focal amplifications, 28 recurrent deletions and up to 10 translocations [5].
Since mutations have normal DNA structure, they cannot be recognized or removed by
DNA repair processes in living cells. Removal of a mutation only occurs if it is sufficiently
deleterious to cause the death of the cell.
Another type of  inheritable alteration,  similar  in some ways to a  mutation,  is  an epige‐
netic  change.  An epigenetic  change refers  to  a  functionally  relevant  modification of  the
DNA,  or  of  the  histone  proteins  controlling  the  relaxation  or  tightened winding  of  the
DNA within their nucleosome structures. Some epigenetic changes involve specific altera‐
tions  of  the  DNA  nucleotides.  Examples  of  such  changes  include  methylation  of  the
DNA at particular sites (CpG islands) where the DNA starts to be transcribed into RNA.
These  changes  may inhibit  transcription.  Other  epigenetic  changes  involve  modification
of histones associated with particular regions of the DNA. These may inhibit or promote
the ability of these regions to be transcribed into mRNA. Methylation of CpG islands or
modification  of  histones  can  directly  alter  transcription  of  gene-encoded  mRNAs  but
they can also occur in parts of the genome that code for microRNAs (miRNAs). MiRNAs
are  endogenous  short  non-protein  coding  RNAs  (~22  nucleotides  long)  that  post-tran‐
scriptionally  regulate  mRNA  expression  in  a  sequence  specific  manner.  miRNAs  either
cause  degradation  of  mRNAs  or  block  their  translation.  Epigenetic  modifications  can
play a role similar to mutation in carcinogenesis,  and about 280 cancer prone epigenetic
alterations are listed by Schnekenburger and Diederich [7]. Epigenetic alterations are usu‐
ally copied onto the daughter chromosomes when the parental chromosome replicates.
Although epigenetic  changes can be passed down from one cell  generation to  the next,
they are  not  regarded as  true  mutations.  Most  epigenetic  changes  appear  to  be  part  of
the differentiation program of the cell and are necessary to allow different types of cells
to carry out different functions. In most cells of a human body, only about 5% of genes
are active at any one time, often due to epigenetic modifications. However, abnormal un‐
programmed epigenetic  changes may also occur  that  alter  the  functioning of  a  cell  and
these changes are referred to as “epimutations.” Programmed epigenetic changes can be
reversed. During development, as daughter cells of a stem cell differentiate, some epige‐
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netic changes are programmed for reversal.  However, a double strand break in DNA (a
type  of  DNA  damage)  can  initiate  unprogrammed  epigenetic  gene  silencing  both  by
causing methylation of a CpG island as well as by promoting silencing types of histone
modifications  [8].  Another  form  of  epigenetic  silencing  may  occur  during  DNA  repair.
The  enzyme  Parp1  (poly(ADP)-ribose  polymerase)  and  its  product  poly(ADP)-ribose
(PAR) accumulate at sites of DNA damage as part of a repair process [9].  This,  in turn,
directs  recruitment  and activation  of  the  chromatin  remodeling  protein  ALC1 that  may
cause nucleosome remodeling [10]. Nucleosome remodeling has been found to cause, for
instance, epigenetic silencing of DNA repair gene MLH1 [11]. Chemicals previously iden‐
tified as DNA damaging agents, including benzene, hydroquinone, styrene, carbon tetra‐
chloride  and  trichloroethylene,  were  shown  to  cause  considerable  hypomethylation  of
DNA, some through the activation of oxidative stress pathways [12]. Dietary agents also
have been shown to affect DNA methylation or histone modification by numerous path‐
ways [13].  Recent  evidence  indicates  that  epimutations  occur  in  DNA repair  genes  that
reduce their  function.  Epimutations in DNA repair  genes allow DNA damages to accu‐
mulate, and are a cause of progression to cancer [14].
2. DNA damages are frequent, and DNA repair processes can be
overwhelmed
Tens of thousands of DNA damages occur per day per cell, on average, in humans, due to
reactive molecules produced by metabolism or by hydrolytic reactions in the warm aqueous
cellular media. Some types of such endogenous damages, and their rates of occurrence, are
shown in Table 1.
A considerable number of other types of endogenous DNA damages have been identified,
many of which are mutagenic. These include propano-, etheno- and malondialdehyde-de‐
rived DNA adducts, base propenals, estrogen-DNA adducts, alkylated bases, deamination
of each of cytosine, adenine and guanine (to form uracil, hypoxanthine and xanthine, re‐
spectively) and adducts formed with DNA by reactive carbonyl species [15].
While there are repair pathways that act on these DNA damages, the repair processes are
not 100% efficient, and further damages occur even as current DNA damages are being re‐
paired. Thus there is a steady state level of many DNA damages, reflecting the efficiencies of
repair and the frequencies of occurrence. For instance, Helbock et al. [16] estimated the
steady state level of oxidative adducts in rat liver as 24, 000 adducts per cell in young rats
and 66, 000 adducts per cell in old rats. Nakamura and Swenberg [17] determined the num‐
ber of AP sites (apurinc and apyrimidinic sites) in normal tissues of the rat (i.e. in lung, kid‐
ney, liver, testis, heart, colon and brain). The data indicated that the number of AP sites
ranged from about 50, 000 per cell in liver, kidney and lung to about 200, 000 per cell in the
brain. These steady state numbers of AP sites in genomic DNA were considered to represent
the balance between formation and repair of AP sites.
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DNA damages Reported rate of occurrence Ref.
Oxidative
86,000 per cell per day in rats [18]
10,000 per cell per day in humans
100,000 per cell per day in rats [19]
11,500 per cell per day for humans
74,000 per cell per day for rats [16]
Specific oxidative damage products 8-
hydroxyguanine, 8-hydroxydeoxyguanosine, 5-
(hydroxymethyl) uracil
2,800 per cell per day in humans
34,800 per cell per day in mice [20]
Depurinations
10,000 per cell during 20-hour generation period [21]
13,920 per cell per day (580/cell/hr) [22]
2,000 to 10,000 per cell per day [23,24]
9,000 per cell per day [25]
Depyrimidinations
500 pyrimidines per cell during 20-hour generation
period [21]
696 per cell per day (29/cell/hr) [22]
Single-strand breaks 55,200 per cell per day (2,300/cell/hr) [22]
Double-strand breaks
~10 per cell cycle in humans [26]
~50 per cell cycle in humans [27]
O6-methylguanine 3,120 per cell per day (130/cell/hr) [22]
Cytosine deamination 192 per cell per day (8/cell/hr) [22]
Table 1. DNA damages due to natural endogenous causes in mammalian cells
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DNA repair pathways are usually able to keep up with the endogenous damages in rep‐
licating cells,  in  part  by halting DNA replication at  the  site  of  damage until  repair  can
occur [28,  29].  In contrast,  non-replicating cells have a build-up of DNA damages, caus‐
ing aging [30, 31].
However, some exogenous DNA damaging agents, such as those in tobacco smoke, dis‐
cussed below, may overload the repair pathways, either with higher levels of the same type
of DNA damages as those occurring endogenously or with novel types of damage that are
repaired more slowly. In addition, if DNA repair pathways are deficient, due to inherited
mutations or sporadic somatic epimutations in DNA repair genes in replicating somatic
cells, unrepaired endogenous and exogenous damages will increase due to insufficient re‐
pair. Increased DNA damages would likely give rise to increased errors of replication past
the damages (by trans-lesion synthesis) or increased error prone repair (e.g. by non-homolo‐
gous end-joining), causing mutations. Increased mutations that activate oncogenes, inacti‐
vate tumor suppressor genes, cause genomic instability or give rise to other driver
mutations in replicating cells would increase the risk of cancer.
3. Cancers are often caused by exogenous DNA damaging agents
Cancer incidence, in different areas of the world, varies considerably. Thus, the incidence of
colon cancer among Black Native-Africans is less than 1 person out of 100, 000, while among
male Black African-Americans it is 72.9 per 100, 000, and this difference is likely due to dif‐
ferences in diet [32, 33]. Rates of colon cancer incidence among populations migrating from
lower-incidence to higher-incidence countries change rapidly, and within one generation
can reach the rate in the higher-incidence country. This is observed, for instance, in migrants
from Japan to Hawaii [34].
The most common cancers for men and women and their rates of incidence per 100, 000,
averaged over the more developed areas and less developed areas of the world, are shown
in Table 2 (from [35]). Overall, worldwide, cancer incidence in all organs combined is 300.1
per 100, 000 per year in more developed areas and 160.3 per 100, 000 per year in less devel‐
oped areas [35]. The differences in cancer incidence between more developed areas of the
world and less developed areas are likely due, in large part, to differences in exposure to
exogenous carcinogenic factors. The lowest rates of cancers in a given organ (Table 2) may
be due, at least in part, to endogenous DNA damages (as described in the previous section)
that cause errors of replication (trans-lesion synthesis) or error prone repair (e.g. non-homol‐
ogous end-joining), leading to carcinogenic mutations. The higher rates (Table 2) are likely
largely attributable to exogenous factors, such as higher rates of tobacco use or diets higher
in saturated fats that directly, or indirectly, increase the incidence of DNA damage.
It is interesting to note in Table 2 that, in cases where cancers occur in the same organs of
men and women, men consistently have a higher rate of cancer than women. The basis for
this is currently unknown.
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More developed areas Less developed areas
Incidence Mortality Incidence Mortality
Breast (women) 66.4 15.3 27.3 10.8
Prostate (men) 62.0 10.6 12.0 5.6
Lung (men) 47.4 39.4 27.8 24.6
Lung (women) 18.6 13.6 11.1 9.7
Colorectum (men) 37.6 15.1 12.1 6.9
Colorectum (women) 24.2 9.7 9.4 5.4
Esophagus (men) 6.5 5.3 11.8 10.1
Esophagus (women) 1.2 1.0 5.7 4.7
Stomach (men) 16.7 10.4 21.1 16.0
Stomach (women) 7.3 4.7 10.0 8.1
Liver (men) 8.1 7.2 18.9 17.4
Liver (women) 2.7 2.5 7.6 7.2
Bladder (men) 16.6 4.6 5.4 2.6
Bladder (women) 3.6 1.0 1.4 0.7
Cervix/Uterine (women) 12.9 2.4 5.9 1.7
Kidney (men) 11.8 4.1 2.5 1.3
Kidney (women) 5.8 1.7 1.4 0.8
Non-Hodgkin lymphoma (men) 10.3 3.6 4.2 3.0
Non-Hodgkin lymphoma
(women) 7.0 2.2 2.8 1.9
Melanoma (men) 9.5 1.8 0.7 0.3
Melanoma (women) 8.6 1.1 0.6 0.3
Ovarian (women) 9.4 5.1 5.0 3.1
Table 2. Incidence and mortality rates for the most common cancers in age standardized rates per 100, 000 (excluding
non-melanoma skin cancer) (Adapted from Jemal et al. [35]).
4. Exogenous DNA damaging agents in carcinogenesis
Carcinogenic exogenous factors have been identified as a major cause of many common can‐
cers, including cancers of the lung, colorectum, esophagus, stomach, liver, cervix/uterus and
melanoma. Often such exogenous factors have been shown to cause DNA damage, as de‐
scribed below.
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5. Exogenous DNA damaging agents in lung cancer
In  both  developed  and  undeveloped  countries,  lung  cancer  is  the  most  frequent  cause
of cancer mortality (Table 2,  data for men and women combined). Lung cancer is large‐
ly  caused  by  tobacco  smoke,  since  risk  estimates  for  lung  cancer  indicate  that,  in  the
United States,  tobacco smoke is  responsible for 90% of  lung cancers.  Also implicated in
lung  cancer  (and  somewhat  overlapping  with  smoking)  are  occupational  exposure  to
carcinogens (approximately 9 to 15%), radon (10%) and outdoor air pollution (perhaps 1
to 2%) [36].
Acrolein 122.4
Formaldehyde 60.5
Acrylonitrile 29.3
1,3-butadiene 105.0
Acetaldehyde 1448.0
Ethylene oxide 7.0
Isoprene 952.0
Benzo[a]pyrene 0.014
Table 3. Weight, in μg per cigarette, of several likely carcinogenic DNA damaging agents in tobacco smoke (from [37]
Cunningham et al., 2011])
Tobacco smoke is a complex mixture of over 5, 300 identified chemicals, of which 150 are
known to have specific toxicological properties (see partial summary by Cunningham [37]).
A “Margin of Exposure” approach has recently been established to determine the most im‐
portant exogenous carcinogenic factors in tobacco smoke [37]. This quantitative-type of
measurement is based on published dose response data for mutagenicity or carcinogenicity
and the concentrations of these components in tobacco smoke (Table 3). Using the “Margin
of Exposure” approach, Cunningham et al. [37] found the most important tumorigenic com‐
pounds in tobacco smoke to be, in order of importance, acrolein, formaldehyde, acryloni‐
trile, 1, 3-butadiene, acetaldehyde, ethylene oxide and isoprene.
Acrolein, the first agent in Table 3, is the structurally simplest α, β-unsaturated aldehyde
(Figure 2). It can rapidly penetrate through the cell membrane and bind to the nucleophilic
N2-amine of deoxyguanine (dG) followed by cyclization of N1, to give the exocyclic DNA
adduct α-hydroxy-1, N2-propano-2’-deoxyguanine (α-HOPdG) (shown in Figure 2) and an‐
other product designated γ-HOPdG. The adducts formed by acrolein are a major type of
DNA damage caused by tobacco smoke, and acrolein has been found to be mutagenic [38].
In tobacco smoke, acrolein has a concentration >8, 000 fold higher than benzo[a]pyrene (re‐
viewed in [38]), with 122.4 μg of acrolein per cigarette. Benzo[a]pyrene has long been
thought to be an important carcinogen in tobacco smoke [39]. As reviewed by Alexandrov et
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al. [39], benzo[a]pyrene damages DNA by forming DNA adducts at the N2 position of gua‐
nine (similar to where acrolein forms adducts). However, by the “Margin of Exposure” ap‐
proach, based on published dose response data and its concentration in cigarette smoke of
0.014 μg per cigarette, benzo[a]pyrene is thought to be a much less important mutagen for
lung tissue than acrolein and the other six highly likely carcinogens in tobacco smoke listed
in Table 3 [37].
The other agents in Table 3 cause DNA damages in different ways. Formaldehyde, the sec‐
ond agent in Table 3, primarily causes DNA damage by introducing DNA-protein cross-
links. These cross-links, in turn, cause mutagenic deletions or other small-scale
chromosomal rearrangements [40] and may also cause mutations through single-nucleotide
insertions [41]. Acrylonitrile, the third agent in Table 3, appears to cause DNA damage indi‐
rectly by increasing oxidative stress, leading to increased levels of 8’-hydroxyl-2-deoxygua‐
nosine (8-OHdG) in DNA [42]. Oxidative stress also causes lipid peroxidation that generates
malondialdehyde (MDA), and MDA forms DNA adducts with guanine, adenine and cyto‐
sine [43]. The fourth agent in Table 3, 1, 3-butadiene, causes genotoxicity both directly by
forming a DNA adduct as well as indirectly by causing global loss of DNA methylation and
histone methylation leading to epigenetic alterations [44]. The fifth agent in Table 3, acetal‐
dehyde, reacts with 2’-deoxyguanosine in DNA to form DNA adducts [45]. The sixth agent
in Table 3, ethylene oxide, forms mutagenic hydroxyethyl DNA adducts with adenine and
guanine [46]. The seventh agent in Table 3, isoprene, is normally produced endogenously by
humans, and is the main hydrocarbon of non-smoking human breath [47]. However, smok‐
ing one cigarette causes an increase of breath isoprene levels by an average of 70% [48]. Iso‐
prene, after being metabolized to mono-epoxides, causes DNA damage measured as single
and double strand breaks in DNA [49].
A large number of studies have been published in which the levels and characteristics of
DNA adducts in the lung and bronchus of smokers and non-smokers have been compared,
as reviewed by Phillips [50]. In most of these studies, significantly elevated levels of DNA
adducts were detected in the peripheral lung, bronchial epithelium or bronchioalveolar lav‐
age cells of the smokers, especially for total bulky DNA adducts. As further discussed by
Phillips [50], mean levels of DNA adducts in ex-smokers (usually with at least a 1 year inter‐
val since smoking cessation) are found generally to be intermediate between the levels of
smokers and life-long non-smokers. From these comparisons, the half-life of some DNA ad‐
ducts in lung tissue are estimated to be ~1–2 years.
6. Exogenous DNA damaging agents in colorectal cancer
Up to 20% of current colorectal cancers in the United States may be due to tobacco smoke
[51]. Presumably tobacco smoke causes colon cancer due to the DNA damaging agents de‐
scribed above for lung cancer. These agents may be taken up in the blood and carried to or‐
gans of the body.
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Figure 2. Reaction of acrolein with deoxyguanosine
The human colon is exposed to many compounds that are either of direct dietary origin or re‐
sult from digestive and/or microbial processes. Four different classes of colonic mutagenic
compounds were analysed by de Kok and van Maanen [52] and evaluated for fecal mutagenici‐
ty. These included (1) pyrolysis compounds from food (heterocyclic aromatic amines and poly‐
cyclic aromatic hydrocarbons), (2) N-nitroso-compounds (from high meat diets, from drinking
water with high nitrates or produced during ulcerative colitis), (3) fecapentaenes (produced by
the colonic bacteria Bacteriodes in the presence of bile acids) and (4) bile acids (increased in the
colon in response to a high fat diet and metabolized to genotoxic form by bacteria in the colon).
Many of these diet-related mutagenic compounds were analysed by Pearson et al. [53] in terms
of their presence in fecal water, and their effect on the cytotoxic or genotoxic activity of fecal
water. Evidence in both of these studies was insufficient to evaluate the colorectal cancer risk as
a result of specific exposures in quantitative terms.
However, substantial evidence implicates bile acids (the 4th possibility above) in colon caner.
Bernstein et al. [54], summarized 12 studies indicating that the bile acids deoxycholic acid
(DCA) and/or lithocholic acid (LCA) induce production of DNA damaging reactive oxygen
species and/or reactive nitrogen species in colon cells of animal or human origin. They also
tabulated 14 studies showing that DCA and LCA induce DNA damage in colon cells. In ad‐
dition to causing DNA damage, bile acids may also generate genomic instability by causing
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mitotic perturbations and reduced expression of spindle checkpoint proteins, giving rise to
micro-nuclei, chromosome bridges and other structures that are precursors to aneuploidy
[55]. Furthermore, at high physiological concentrations, bile acids cause frequent apoptosis,
and those cells in the exposed populations with reduced apoptosis capability tend to survive
and selectively proliferate [54, 56]. Cells with reduced ability to undergo apoptosis in re‐
sponse to DNA damage would tend to accumulate mutations when replication occurs past
those damages, and such cells may give rise to colon cancers. In addition, 7 epidemiological
studies between 1971 and 1990 (reviewed by Bernstein et al. [54]), found that fecal bile acid
concentrations are increased in populations with a high incidence of colorectal cancer. A
similar 2012 epidemiological study showed that concentrations of fecal LCA and DCA, re‐
spectively, were 4-fold and 5-fold higher in a population at 65-fold higher risk of colon can‐
cer compared to a population at lower risk of colon cancer [32]. This evidence points to bile
acids DCA and LCA as centrally important DNA-damaging carcinogens in colon cancer.
Dietary total fat intake and dietary saturated fat intake is significantly related to incidence of
colon cancer [57]. Increasing total fat or saturated fat in human diets results in increases in
DCA and LCA in the feces [58, 59], indicating increased contact of the colonic epithelium
with DCA and LCA. Bernstein et al. [60] added the bile acid DCA to the standard diet of
wild-type mice. This supplement raised the level of DCA in the feces of mice from the stand‐
ard-diet fed mouse level of 0.3 mg DCA/g dry weight to 4.6 mg DCA/g dry weight, a level
similar to that for humans on a high fat diet of 6.4 mg DCA/g dry weight. After 8 or 10
months on the DCA-supplemented diet, 56% of the mice developed invasive colon cancer.
This directly indicates that DCA, a DNA damaging agent, at levels present in humans after a
high fat diet, can cause colorectal cancer.
7. Exogenous DNA damaging agents implicated in other major cancers
It is beyond the scope of this chapter to detail the evidence implicating DNA damaging
agents as etiologic agents in all of the significant cancers. Therefore, in Table 4 we indicate
with a single reference the major DNA damaging agent in five additional prevalent cancers,
in order to illustrate the generality of exogenous DNA damaging agents as causes of cancer.
In particular, we point out, as reviewed by Handa et al. [61], Helicobacter pylori infection in‐
creases the production of reactive oxygen and reactive nitrogen species (RNS) in the human
stomach, which, in turn, significantly increases DNA damage in the gastric epithelial cells.
Thus, H. pylori infection acts as a DNA damaging agent. In the case of human papillomavi‐
rus (HPV) infection, Wei et al. [62] showed that cervical cells could resist RNS stress when
not infected with HPV. However, cervical cells infected by HPV and exposed to RNS had
higher levels of DNA double strand breaks as well as a higher mutation rate. This appeared
to occur due to the ability of HPV to greatly reduce protein expression of the DNA damage
repair/response gene P53 when infected cells were stressed by RNS. Since reduced P53 ex‐
pression leads to greater RNS-induced DNA damage, HPV infection acts as a DNA damag‐
ing agent in the presence of RNS stress.
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Cancer Exogenous DNA damaging agent Ref.
Esophagus Bile acids [63]
Stomach Helicobacter pylori infection [61]
Liver Aspergillus metabolite aflatoxin B(1) [64]
Cervix/Uterus Human papillomavirus plus increased nitric oxide from tobacco smoke orother infection [62]
Melanoma UV light from solar radiation [65]
Table 4. Selected cancers and relevant implicated exogenous DNA damaging agents
8. Deficient DNA repair due to a germ line mutation allows DNA
damages to increase, leading to increased frequencies of mutation,
epimutation and cancer
Expression of DNA repair genes may be reduced by inherited germ line mutations or genet‐
ic polymorphisms, or by epigenetic alterations or mutations in somatic cells, and these re‐
ductions may substantially increase the risk of cancer. Overall, about 30% of cancers are
considered to be familial (largely due to inherited germ line mutations or genetic polymor‐
phisms) and 70% are considered to be sporadic [66].
In 2 overlapping databases [67, 68] 167 and169 human genes (depending on the database)
are listed that are directly employed in DNA repair or influence DNA repair processes. The
lists were originally devised by Wood et al. [69, 70]. The genes are distributed in groups of
DNA repair pathways and in related functions that affect DNA repair (Table 5). Bernstein et
al. [71] illustrate many of the steps and order of action of the gene products involved for the
first five DNA repair pathways listed in Table 5.
Individuals with an inherited impairment in DNA repair capability are often at considerably
increased risk of cancer. If an individual has a germ line mutation in a DNA repair gene or a
DNA damage response gene (that recognizes DNA damage and activates DNA repair), usu‐
ally one abnormal copy of the gene is inherited from one of the parents and then the other
copy is inactivated at some later point in life in a somatic cell. The inactivation may be due,
for example, to point mutation, deletion, gene conversion, epigenetic silencing or other
mechanisms [72]. The protein encoded by the gene will either not be expressed or be ex‐
pressed in a mutated form. Consequently the DNA repair or DNA damage response func‐
tion will be deficient or impaired, and damages will accumulate. Such DNA damages can
cause errors during DNA replication or inaccurate repair, leading to mutations that can give
rise to cancer.
Increased oxidative DNA damages also cause increased gene silencing by CpG island hy‐
permethylation, a form of epimutation. These oxidative DNA damages induce formation
and relocalization of a silencing complex that may result in cancer-specific aberrant DNA
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methylation and transcriptional silencing [73]. As pointed out above, the enzyme Parp1
(poly(ADP)-ribose polymerase) and its product poly(ADP)-ribose (PAR) accumulate at sites
of DNA damage as part of a repair process [9], recruiting chromatin remodeling protein
ALC1, causing nucleosome remodeling [10] that has been shown to direct epigenetic silenc‐
ing of DNA repair gene MLH1 [11]. If silencing of genes necessary for DNA repair occurs,
the repair of further DNA damages will be deficient and more damages will accumulate.
Such additional DNA damages will cause increased errors during DNA synthesis, leading
to mutations that can give rise to cancer.
Number of genes listed in the two
databases
Homologous Recombinational Repair (HRR) 21,21
Non-homologous End Joining (NHEJ) 8,7
Nucleotide Excision Repair (NER) 30,29
Base Excision Repair (including PARP enzymes) (BER) 19,20
Mis-Match Repair (MMR) 11,10
Fanconi Anemia (FANC) [affects HRR (above) and translesion synthesis (TLS)] 10,16
Direct reversal of damage 3,3
DNA polymerases (act in various pathways) 17,15
Editing and processing nucleases (act in various pathways) 6,8
Ubiquitination and modification/Rad6 pathway including TLS 11,5
DNA damage response 12,14
Modulation of nucleotide pools 3,3
Chromatin structure 2,3
Defective in diseases and syndromes 4,5
DNA-topoisomerase crosslinks 2,1
Other genes 8,9
Table 5. DNA repair pathways and other processes affecting DNA repair [67, 68]
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9. Inherited mutations in genes employed in DNA repair that give rise to
syndromes characterized by increased risk of cancer.
Table 6 lists 36 genes for which an inherited mutation results in an increased risk of cancer.
The proteins encoded by 35 of these genes are involved in DNA repair and in some cases
also in other aspects of the DNA damage response such as cell cycle arrest and apoptosis.
The polymerase coded for by the 36th gene, XPV (POLH), is involved in bypass (rather than
repair) of DNA damage, called translesion synthesis. The genes listed in Table 6, when mu‐
tated in the germ line, give rise to a considerably increased lifetime risk of cancer, of up to
100% (e.g. p53 mutations [74]). Thus defects in DNA repair cause progression to cancer.
In addition to mutations in genes that may substantially raise lifetime cancer risk, there appear to
be many weakly effective genetically inherited polymorphisms [single nucleotide polymo‐
phisms (SNPs) and copy number variants (CNVs)]. By the HapMap Project, more than 3 million
SNPs have been found, and by Genome Wide Association studies (GWAs), about 30 SNPs were
found to increase risk of cancers. However the added risk of cancer by these SNPs is usually
small, i.e. less than a factor of 2 increase [75]. A large twin study [66], involving 44, 788 pairs of
twins, evaluated the risk of the same cancer before the age of 75 for monozygotic twins (identical
genomes with the same polymorphisms) and dizygotic twins (having a 50% chance of the same
polymorphisms). If one twin had colorectal, breast or prostate cancer, the monozygotic twin had
an 11 to 18 percent chance of developing the same cancer while the dizygotic twin had only a 3 to
9% risk. The differences in monozygotic and dizygotic rates of paired cancer were not significant
for the other 24 types of cancer evaluated in this study. Polymorphisms of the DNA repair gene
ERCC1 will be discussed below in relation to targeted chemotherapy.
10. Epimutations may repress DNA repair gene expression, allowing
DNA damages to increase, leading to increased frequency of further
epimutation, mutation and cancer
While germ line (familial) mutations in DNA repair genes cause a high risk of cancer, somat‐
ic mutations in DNA repair genes are rarely found in sporadic (non-familial) cancers [4].
Much more often, DNA repair genes are found to have epigenetic alterations in cancers.
One example of the epigenetic down-regulation of a DNA repair gene in cancers comes from
studies of the MMR protein MLH1. Truninger et al. [76] assessed 1, 048 unselected consecutive
colon cancers. Of these, 103 were deficient in protein expression of MLH1, with 68 of these can‐
cers being sporadic (the remaining MLH1 deficient cancers were due to germ line mutations). Of
the 68 sporadic MLH1 protein-deficient colon cancers, 65 (96%) were found to be deficient due to
epigenetic methylation of the CpG island of the MLH1 gene. Deficient protein expression of
MLH1 may also have been caused, in the remaining 3 sporadic MLH1 protein-deficient cancers
(which did not have germ line mutations), by over expression of the microRNA miR-155. When
miR-155 was transfected into cells it caused reduced expression of MLH1 [77]. Overexpression
of miR-155 was found in colon cancers in which protein expression of MLH1 was deficient and
the MLH1 gene was neither mutated nor hypermethylated in its CpG island [77].
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DNA repair gene(s) Encodedprotein
Repair pathway(s)
affected Ref.
Cancers with
increased risk Ref.
breast cancer 1 & 2 BRCA1,BRCA2
HRR of double strand breaks
and daughter strand gaps [85] Breast, Ovarian [86]
ataxia telangiectasia mutated ATM
Different mutations in ATM
reduce HRR, single strand
annealing (SSA), NHEJ or
homology directed double
strand break rejoining
(HDR)
[87] Leukemia, Lymphoma,Breast [87,88]
Nijmegen breakage syndrome NBS NHEJ [89] Lymphoid cancers [89]
meiotic recombination 11 MRE11 HRR and NHEJ [90] Breast [91]
Bloom’s Syndrome (helicase) BLM HRR [92]
Leukemia, Lymphoma,
Colon, Breast, Skin,
Auditory canal, Tongue,
Esophagus, Stomach,
Tonsil, Larynx, Lung,
Uterus
[93]
Werner Syndrome (helicase) WRN HRR, NHEJ, long patch BER [94]
Soft tissue sarcoma,
Colorectal, Skin,
Thyroid,
Pancreatic
[95]
Rothman Thomson syndrome
Rapadilino syndrome
Baller Gerold syndrome
RECQ4 Helicase likely active in HRR [96]
Basal cell carcinoma,
Squamous cell
carcinoma,
Intraepidemial
carcinoma
[97]
Fanconi’s anemia gene FANC
A,B,C,D1,D2,E,F,G,I,J,L,M,N FANCA etc. HRR and TLS [98]
Leukemia, Liver tumors,
Solid tumors many
areas
[99]
xeroderma pigmentosa
C, E [DNA damage binding
protein 2 (DDB2)]
XPC
XPE
Global genomic NER repairs
damage in both transcribed
and untranscribed DNA
[100,
101]
Skin cancer (melanoma
and non-melanoma)
[100,
101]
xeroderma pigmentosa
A, B, D, F, G
XPA XPB
XPD XPF
XPG
Transcription coupled NER
repairs the transcribed
strands of transcriptionally
active genes
[102]
Skin cancer (melanoma
and non-melanoma),
Central nervous system
cancers
[102]
xeroderma pigmentosa V (also
called polymerase H)
XPV
(POLH) Translesion Synthesis (TLS) [102]
Skin cancer (melanoma
and non-melanoma) [102]
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DNA repair gene(s) Encodedprotein
Repair pathway(s)
affected Ref.
Cancers with
increased risk Ref.
mutS (E. coli) homolog 2
mutS (E. coli) homolog 6
mutL (E. coli) homolog 1
postmeiotic segregation
increased 2 (S. cerevisiae)
MSH2
MSH6
MLH1
Pms2
MMR [76] Colorectal, endometrial.ovarian [103]
mutY homolog (E. coli) MUTYH BER of A mispaired with8OHdG, G, FapydG and C [104] Colon [105]
ataxia telaniectsia and RAD3
related ATR
DNA damage response
likely affects HRR, not NHEJ [106] Oropharyngeal cancer [107]
Li Fraumeni syndrome P53
HRR, BER, NER and DNA
Damage Response for those
and for NHEJ and MMR
[108]
Sarcoma, Breast, Lung,
Skin, Pancreas,
Leukemia, Brain
[74]
Table 6. Inherited mutations in DNA repair genes that increase the risk of cancer
Another example of the epigenetic down-regulation of a DNA repair gene in cancer comes from
studies of the direct reversal of methylated guanine bases by methyl guanine methyl transferase
(MGMT). In the most common form of brain cancer, glioblastoma, the DNA repair gene MGMT
is epigenetically methylated in 29% [78] to 66% [79] of tumors, thereby reducing protein expres‐
sion of MGMT. However, for 28% of glioblastomas, the MGMT protein is deficient but the
MGMT promoter is not methylated [79]. Zhang et al. [78] found, in the glioblastomas without
methylated MGMT promoters, that the level of microRNA miR-181d is inversely correlated
with protein expression of MGMT and that the direct target of miR-181d is the MGMT mRNA
3’UTR (the three prime untranslated region of MGMT mRNA), though they indicated that other
miRNAs may also be involved in the reduction of protein expression of MGMT.
Almost all DNA repair deficiencies found, so far, in sporadic cancers, and in precancerous
tissues surrounding cancers (field defects) are due to epigenetic changes. Examples of such
epigenetic alterations in DNA repair genes in different types of cancer are shown in Table 7.
A recent review [80] lists 41 reports (mostly not overlapping with those listed in Table 7)
indicating methylation of 20 DNA repair genes in various cancers. In Table 7 data are also
shown on DNA repair gene deficiencies for the field defects associated with colorectal, gas‐
tric, laryngeal and non-small cell lung cancer.
As summarized above, epimutations can result from oxidative DNA damages. Such damages
cause formation and relocalization of a silencing complex that in turn causes increased gene si‐
lencing by CpG island hypermethylation [73]. Epigenetic nucleosome remodeling during DNA
repair can also silence gene expression [11]. When CpG island methylation or nucleosome re‐
modeling or other types of epigenetic alterations (e.g. micro RNAs or histone modifications) in‐
hibit DNA repair genes, more damages will accumulate. Accumulated DNA damages cause
increased errors during DNA synthesis and repair. Thus epigenetic deficiencies in DNA repair
genes can have a cascading effect (a mutator phenotype), leading to genomic instability and ac‐
cumulation of mutations and epimutations that can give rise to cancer.
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Cancer
Epigenetic changes
in cancer
(mechanism)
% sporadic cancers
with epimutations
Epigenetic
changes in field
defect
(mechanism)
% field defects
with epi-
mutations
Ref.
Breast
BRCA1 (CGI*)
13% unselected
[108]67% medullary
55% mucinous
WRN (CGI) 17% unselected [2]
Ovarian BRCA1 (CGI)
31% of those with
loss of
heterozygosity
[108]
Colorectal
WRN (CGI) 38% [2]
MGMT (CGI) 46% MGMT (CGI) 23% [109]
MGMT (CGI) 90%
[110]
MLH1 (CGI) 65%
MLH1 (CGI) 10% [76]
MLH1 (CGI) 2%
[111]MSH2 (CGI) 13% MSH2 5%
MGMT (CGI) 47% MGMT 11%
ERCC1 100% ERCC1 40%
[112]PMS2 88% PMS2 50%
XPF 55% XPF 40%
Gastric
MGMT (CGI) 88% MGMT (CGI) 29% [113]
WRN (CGI) 25% [2]
Esophageal
squamous cell
carcininoma
MLH1 (CGI) 49%
[114,115]MLH2 (CGI) 35%
MGMT (CGI) 41%
Larynx MGMT (CGI) 54% MGMT (CGI) 38% [116]
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Cancer
Epigenetic changes
in cancer
(mechanism)
% sporadic cancers
with epimutations
Epigenetic
changes in field
defect
(mechanism)
% field defects
with epi-
mutations
Ref.
Non-small cell Lung
WRN (CGI) 38% [2]
MGMT (CGI) 70% MGMT (CGI) 40% [117]
Prostate WRN (CGI) 20% [2]
Thyroid WRN (CGI) 13% [2]
Non-Hodgkin
lymphoma WRN (CGI) 24% [2]
Leukemias WRN (CGI) 5-10% [2]
Chondrosarcomas WRN (CGI) 33% [2]
Osteosarcomas WRN (CGI) 11% [2]
Brain glioblastoma
MGMT (CGI) 51% [118]
MGMT (miRNA) 28% [78]
Liver hepatocellular
carcinoma
P53 (non-CGI
promoter site specific
methylation)
100% [119]
Papillary thyroid
(tested 23 DNA repair
genes for CGI)
MLH1 (CGI) 21%
[120]PCNA (CGI) 13%
OGG1 (CGI) 2%
*CGI=CpG island methlyation
Table 7. Examples of epigenetic alterations (epimutations) of DNA repair genes in cancers and in field defects, with
mechanisms indicated where known.
Deficiencies in DNA repair genes cause increased mutation rates. Mutations rates increase
in MMR defective cells [81, 82] and in HRR defective cells [83]. Chromosomal rearrange‐
ments and aneuploidy also increase in HRR defective cells [84]. Thus, deficiency in DNA re‐
pair causes genomic instability and genomic instability is the likely main underlying cause
of the genetic alterations leading to tumorigenesis. Deficient DNA repair permits the acquis‐
ition of a sufficient number of alterations in tumor suppressor genes and oncogenes to fuel
carcinogenesis. Deficiencies in DNA repair appear to be central to the genomic and epige‐
nomic instability characteristic of cancer.
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Figure  3  illustrates  the  chain  of  consequences  of  exposure  of  cells  to  endogenous  and
exogenous  DNA damaging agents  that  lead to  cancer.  The  role  of  germ line  defects  in
DNA repair  genes in familial  cancer are also indicated.  The large role  of  DNA damage
and  consequent  epigenetic  DNA  repair  defects  leading  to  sporadic  cancer  are  empha‐
sized.  The roles of  germ line mutation and directly induced somatic  mutation in spora‐
dic cancer are indicated as well.
Figure 3. The roles of DNA damage, epigenetic deficiencies in DNA repair and mutation in progression to cancer.
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11. Epigenetic alterations caused by micro RNAs
MicroRNAs (miRNAs) are endogenous non-coding RNAs, 19-25 nucleotides in length, that
can have substantial effects on DNA repair. miRNAs can either directly or indirectly reduce
expression of DNA repair or DNA damage response genes. As discussed above, over-ex‐
pression of miR-155 causes reduced expression of DNA repair protein MLH1, and miR-155
is overexpressed in colon cancers [77] (curved arrow in Figure 3). Similarly, miR-181d is
overexpressed in glioblastomas, causing reduced expression of DNA repair protein MGMT
[78]. Although miRNAs can epigenetically regulate DNA repair gene expression, the expres‐
sion levels of many miRNAs may themselves be subject to epigenetic regulation. One mech‐
anism of epigenetic regulation of miRNA expression is hypomethylation of the promoter
region of the DNA sequence that codes for the miRNA. Schnekenburger and Diederich [7]
list miR-155 as one of a long list of mi-RNAs whose expression is increased by hypomythy‐
lation in colorectal cancers. In particular, hypomethylated miR-155 (the hypomethylation
making it more active) targets genes MLH1, MSH2 and MSH6, causing each of them to have
reduced expression [7].
Wan et al. [121] referred to 6 further DNA repair genes that are directly targeted by miR‐
NAs. ATM, RAD52, RAD23B, MSH2, BRCA1 and P53, are each specifically targeted by one
or two of the 8 miRNAs miR-21, miR-24, miR-125b, miR-182, miR-210, miR-373, miR-421
and miR-504, with all but miR-210, miR-421 and miR-504 among those identified by Schne‐
kenburger and Diederich [7] as overexpressed through epigenetic hypomethylation. Overex‐
pression of any one of these miRNAs leads to reduced expression of its target DNA repair
gene. Wan et al. [121] further listed 16 DNA damage response genes targeted by specific
miRNAs. Wan et al. [121] indicated miR-15a, miR-16, miR-17, miR-20a, miR-21, miR-24,
miR-29, miR-34a, miR-106a, miR-93, miR-124a, miR-125b, miR-192, miR-195, miR-215,
miR-182, miR-373 as among those targeting DNA damage response genes. Of these, all but
miR-124a were identified by Schnekenburger and Diederich [7], (and Malumbres [122] fur‐
ther identified miR-34a and miR-124a) as being among miRNAs whose expression is subject
to epigenetic alteration in tumors. Other miRNAs whose expression is subject to epimuta‐
tion in colorectal cancers (and their target DNA repair or DNA damage response genes) in‐
clude miR-17 (E2F1), miR-34b/c (P53), miR-106a (E2F1), miR-200a and miR-200b (MLH1,
MSH2) and miR-675 (Rb) [7].
12. Epigenetic alterations caused by chromosome remodeling and histone
modification
Specific miRNAs can also indirectly (and strongly) reduce protein expression of DNA repair
genes through their role in repression of proteins designated High Mobility Group A1
(HMGA1) and HMGA2 (the names come from the proteins’ high electrophoretic mobility on
acrylamide gels). HMGA1 and HMGA2 cause chromatin remodeling at specific sites in
DNA and reduce expression at those sites. In particular, these proteins appear to control
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DNA repair genes BRCA1 and ERCC1. BRCA1 And ERCC1 proteins have key roles in DNA
repair, particularly of double-strand breaks and interstrand crosslinks. HMGA1 and HMGA2
genes are usually active in embryogenesis, but normally have very low expression levels in
adult tissues. Their expression levels in adult tissues are kept low by the actions of specific
miRNAs. If expression of these miRNAs is reduced, then the repressive HMGA1 and
HMGA2 proteins become highly expressed and, in particular, can reduce expression of
BRCA1 or ERCC1 respectively.
As reviewed by Resar [123], all HMG proteins share an acidic carboxyl terminus and asso‐
ciate with chromatin. As an example, HMGA1A, in particular, has three AT-hook domains
that allow it to bind to AT-rich regions and recruit an “enhanceosome” that may displace
histones and cause chromosome remodeling and reduce gene expression. Baldassarre et al.
[124] showed that HMGA1B protein binds to the promoter region of BRCA1 and inhibits
BRCA1 promoter activity (indicated in Figure 3 as chromatin remodeling causing reduced
BRCA1). In 12 surgically removed human breast carcinomas, there was an inverse correla‐
tion between HGMA1 protein and BRCA1 mRNA levels. HGMA1 was almost undetectable
in normal breast tissue, highly expressed in the tumor samples, and BRCA1 protein was
strongly diminished in tumor samples. Baldassarre et al. [124] suggested that while only
11% of breast tumors had hypermethylation of the BRCA1 gene, 82% of aggressive breast
cancer specimens have low BRCA1 protein, and most of these could be due to chromatin re‐
modeling by high levels of HMGA1 protein.
Similarly, HMGA2 binds to an ERCC1 promoter site and represses ERCC1 promoter activity
[125]. The miRNAs miR-23a, miR-26a and miR-30a inhibit HMG2A protein expression [126]
though it has not been reported whether these miRNAs are under epigenetic control. In Fig‐
ure 3, one of two dotted lines is used to indicate possible repression of ERCC1 by epigeneti‐
cally induced chromatin remodeling.
Resar [123] and Baldassarre et al. [124] summarized reports indicating that HGMA1 is wide‐
ly overexpressed in aggressive malignancies including cancers of the thyroid, head and
neck, colon, lung, breast, pancreas, hematopoetic system, cervix, uterine corpus, prostate
and central nervous system. Palmieri et al. [127] showed that HGMA1 and HMGA2 are tar‐
geted (and thus strongly reduced in expression) by miR-15, miR-16, miR-26a, miR-196a2 and
Let-7a. The promoter regions associated with miR-16, miR-196a2 and Let-7a miRNAs are ep‐
imutated by hypomethylation [7, 122] while Sampath et al. [128] showed, in addition, that
the coding regions for miR-15 and miR-16 were epigenetically silenced due to histone deace‐
tylase activity. Palmieri et al. [127] further showed that these 5 miRNAs are drastically re‐
duced in a panel of 41 pituitary adenomas, accompanied by increases in HMGA1 and
HMGA2 specific mRNAs. In a more recent study on pituitary adenomas by D’Angelo et al.
[129], reduced expression of 18 miRNAs was found, with 5 of them targeting HMGA1 or
HMGA2. In this recent study, among the 18 miRNAs with reduced expression, the reduced
expression of miR-26b, miR-34b, miR-432 and miR-592 was known to be due to epigenetic
alteration [7, 122]. Thus, epigenetic miRNA silencing, causing strong expression of HMGA1
and HMGA2, occurs in many types of cancer and this may be related to reductions found in
expression of DNA repair genes BRCA1, BRCA2 and ERCC1.
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Suzuki et al. [130], using genome wide profiling, found 174 primary transcription units for
miRNAs, called “pri-miRNAs” (large precursor RNAs which may encode multiple miR‐
NAs), of which they identified 37 as potential targets for epigenetic silencing. Of these 37
pri-miRNAs, 22 were encoded by DNA sequences with CpG islands (all of which were hy‐
permethylated in colorectal cancer cells) while the other pri-miRNAs were subject to regula‐
tion by epigenetic “activating marks” without evidence of deregulated methylation.
Activating marks are alterations on histones that cause transcriptional activation of the
genes associated with those altered histones (reviewed by Tchou-Wong et al. [131]). In par‐
ticular, the nucleosome, the fundamental subunit of chromatin, is composed of 146 bp of
DNA wrapped around an octamer of four core histone proteins (H3, H4, H2A, and H2B).
Posttranslational modifications (i.e., acetylation, methylation, phosphorylation, and ubiqui‐
tination) of the N- and C-terminal tails of the four core histones play an important role in
regulating chromatin biology. These specific histone modifications, and their combinations,
are translated, through protein interactions, into distinct effects on nuclear processes, such
as activation or inhibition of transcription. In eukaryotes, methylation of lysine 4 in histone
H3 (H3K4), which interacts with the promoter region of genes, is linked to transcriptional
activation. There is a strong positive correlation between trimethylation of H3K4, transcrip‐
tion rates, active polymerase II occupancy and histone acetylation. Thus trimethylation of
H3K4 is an activating mark.
In addition to pri-miRNAs being regulated by activating marks, some miRNAs appear to be
directly regulated by these histone modifications. As summarized by Sampath et al. [128],
histone deacetylases catalyze the removal of acetyl groups on specific lysines around gene
promoters to trigger demethylation of otherwise methylated lysine 4 on histones
(H3K4me2/3) and this causes loss of these activating marks, promoting chromatin compac‐
tion, and leading to epigenetic silencing. Sampath et al. [128] showed that such histone de‐
acetylase activity mediates the epigenetic silencing of miRNAs miR-15a, miR-16, and
miR-29b. As indicated above, miR-15, miR-16 specifically target HGMA1 and HMGA2. If
miR-15 and miR-16 lose their activating marks, they have reduced expression, causing
HGMA1 and HGMA2 to be transcriptionally activated, thus reducing expression of DNA re‐
pair genes BRCA1 and ERCC1.
In Figure 3, histone modification and chromatin remodeling are indicated as epigentically
altering the expression of many genes in progression to cancer, and specifically causing re‐
duced BRCA1 and possibly (as indicated by one dotted line) reduced expression of ERCC1.
In addition, a second dotted line is used to indicate possible repression of ERCC1 by an miR‐
NA. Klase et al. [132] showed that a particular virally coded miRNA down regulates ERCC1
protein expression at the p-body level (a p-body is a cytoplasmic granule “processing body”
that interacts with miRNAs to repress translation or trigger degradation of target mRNAs).
A survey of human miRNA homology regions to ERCC1 mRNA indicates at least 21 human
coded miRNAs that could act to decrease ERCC1 mRNA translation (shown in Microcosm
Targets [133]). ERCC1 protein expression, assessed by immunohistochemical staining, is de‐
ficient due to an epigenetic mechanism in colon cancers [110], and this could be due to ac‐
tion of one or more miRNAs, acting directly on ERCC1 mRNA.
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13. Driver mutations and pathways to cancer progression
Recent research indicates a mechanism by which an early driver mutation may cause subse‐
quent epigenetic alterations or mutations in pathways leading to cancer. Wang et al. [134]
point out that isocitrate dehydrogenase genes IDH1 and IDH2 are the most frequently mu‐
tated metabolic genes in human cancer. A gene frequently mutated in cancer is considered
to be a driver mutation [4] so that mutations in IDH1 and IDH2 would be driver mutations.
Wang et al. [134] further point out that IDH1 and IDH2 mutant cells produce an excess met‐
abolic intermediate, 2-hydroxyglutarate, which binds to catalytic sites in key enzymes that
are important in altering histone and DNA promoter methylation. Thus, mutations in IDH1
and IDH2 generate a DNA CpG island methylator phenotype that causes promoter hyper‐
methylation and concomitant silencing of tumor suppressor genes such as the DNA repair
genes MLH1, MGMT and BRCA1. As shown in Figure 3, a driver mutation in IDH1 can
cause a feedback loop leading to increased DNA repair deficiency, further mutations and
epimutations, and consequent accelerated tumor progression.
A study, involving 51 patients with brain gliomas who had two or more biopsies over time,
showed that mutation in the IDH1 gene occurred prior to the occurrence of a p53 mutation
or a 1p/19q loss of heterozygosity, indicating that IDH1 mutation is an early driver mutation
[135]. Work by Turcan et al. [136] showed that IDH1 mutation alone is sufficient to establish
the brain glioma CpG island methylator phenotype. Carillo et al. [137] showed that when an
IDH1 mutation was present in glioblastoma tumors, 64% of these were hypermethylated in
the promoter regions of MGMT.
Other initial driver mutations can cause progression to glioblastoma as well. As pointed out
above, increased levels of miR-181d also cause reduced expression of MGMT protein in glio‐
blastoma. Nelson et al. [138] indicate that a single type of miRNA may target hundreds of
different mRNAs, causing alterations in multiple pathways. Patients with a glioblastoma
that does not harbor an IDH1 mutation have an overall fairly short survival time, while pa‐
tients with both mutated IDH1 and methylated MGMT have a subtype of glioblastoma with
a much longer survival time (implying a different pathway of cancer progression) [137].
An IDH1 mutation that gives rise to a CpG island methylator phenotype that causes pro‐
moter hypermethylation and concomitant silencing of MGMT also causes promoter silenc‐
ing of other genes as well. In addition to silencing of genes, the CpG island methylator
phenotype can cause methylation of the promoter regions of long interspersed nuclear ele‐
ment-1 (LINE-1) DNA sequences. Ohka et al. [139] point out that LINE-1 is a class of retro‐
posons that are the most successful integrated mobile elements in the human genome, and
account for about 18% of human DNA. Ohka et al. [139] found that LINE-1 methylation is
directly proportional to MGMT promoter methylation in gliomas and suggested that LINE-1
methylation could be used as a proxy to indicate the CpG island methylator phenotype sta‐
tus in glioblastomas. This phenotype, likely associated with methylation of the MGMT pro‐
moter, in turn, indicates whether treatment with the DNA alkylating agent temozolomide
will be beneficial in treatment of a patient with a glioblastoma, since MGMT removes the
alkyl groups added to guanine by temozolomide.
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14. Field defects
Field defects have been described in many types of gastrointestinal cancers [140]. A field de‐
fect arises when an epimutation or mutation occurs in a stem cell that causes that stem cell
to give rise to a number of daughter stem cells that can out-compete neighboring stem cells.
These initial mutated cells form a patch of somewhat more rapidly growing cells (an initial
field defect). That patch then enlarges at the expense of neighboring cells, followed by, at
some point, an additional mutation or epimutation arising in one of the field defect stem
cells so that this new stem cell with two advantageous mutations can generate daughter
stem cells that can out-compete the surrounding field defect of cells that have just one ad‐
vantageous mutation. As illustrated in Figure 4, this process of expanding sub-patches with‐
in earlier patches will occur multiple times until a particular constellation of mutations
results in a cancer (represented by the small dark patch in Figure 4. It should also be noted
that a cancer, once formed, continues to evolve and continues to produce sub clones. A renal
cancer, sampled in 9 areas, had 40 ubiquitous mutations, 59 mutations shared by some, but
not all regions, and 29 “private” mutations only present in one region [141].
 
. 
Figure 4. Schematic of a field defect in progression to cancer
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Figure 5. Colon resection including a colon cancer. Dashed arrows indicate grossly unremarkable colonic mucosa. Ul‐
cerated hemorrhagic mass represents a moderately differentiated invasive adenocarcinoma. Solid arrow indicates the
heaped up edge of the malignant ulcer
Figure 5 shows an opened resected segment of a human colon that has a colon cancer. As
illustrated by Bernstein et al. [142], there are about 100 colonic microscopic epithelial crypts
per sq mm in the colonic epithelium. The resection shown in Figure 5 has an area of about
6.5 cm by 23 cm, or 150 sq cm, or 15, 000 sq mm. Thus this area has about 1.5 million crypts.
There are 10-20 stem cells at the base of each colonic crypt [143, 144]. Therefore there are
likely about 15 million stem cells in the grossly unremarkable colonic mucosal epithelium
shown in Figure 5. Evidence reported by Facista et al. [112], and listed in Table 7, indicates
that in many such resections, most of the stem cells in such an area up to 10 cm distant (in
each direction) from a colon cancer (such as in the grossly unremarkable area shown in Fig‐
ure 5), and the majority of their differentiated daughter cells, are epigenetically deficient for
protein expression of the DNA repair genes ERCC1, PMS2 and/or XPF, although the epithe‐
lium is histologically normal.
The stem cells most distant from the cancer, deficient for ERCC1, PMS2 and/or XPF, can be
considered to constitute an outer ring, and be deficient as well in the inner rings, of a field
defect schematically illustrated in Figure 4. The outer ring in Figure 4 includes, within its
circumscribed area, on the order of 15 million stem cells, presumably arising from an initial
progenitor stem cell deficient in DNA repair (due to epigenetic silencing). As a result of this
repair deficit, the initial stem cell was genetically unstable, giving rise to an increased fre‐
quency of mutations in its decendents. One daughter stem cell among its decendents had a
mutation that, by chance, provided a replicative advantage. This descendent then under‐
went clonal expansion because of its replicative advantage. Among the further decendents
of the clone, new mutations arose frequently, since these descendents had a mutator pheno‐
type [145], due to the repair deficiency passed down epigenetically from the original repair-
defective stem cell. Among these new mutations, some would provide further replicative
advantages, giving rise to a succession of more aggressively growing sub clones (inner
rings), and eventually a cancer.
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15. Exogenous carcinogenic agents cause reduced expression of DNA
repair genes
Many known carcinogenic agents cause reduced expression of DNA repair genes or directly
inhibit the actions of DNA repair proteins. Table 8 lists examples of carcinogens that have
such effects. Due to space limitations, many other such carcinogens are not listed. These
findings further link DNA damage to cancer.
Carcinogens Inhibit DNA Repair Gene Mechanism Shown Ref.
Arsenic compounds
PARP [146,147]
XRCC1
[146,148]Ligase 3
Ligase 4
DNA POLB, XRCC4
[146]
DNA PKCS, TOPO2B
OGG1, ERCC1, XPF [149]
XPB, XPC, XPE [150]
P53 Inhibition of P53 serine 15phosphorylation [151]
Cadmium compounds
MSH2, ERCC1, XRCC1
Promoter methylation [152]
OGG1
MSH2, MSH6 proteins Cd2+ binds to proteins [153]
OGG1 protein Oxidation of Ogg1 [154]
DNA-PK, XPD [155]
XPC [156]
Bile acids
deoxycholate
MUTYH, OGG1 mRNA reduced [157]
BRCA1 [158]
lithocholate DNA POLB [159]
Lipid peroxidation
compounds
4-hydroxy-2-nonenal (4-HNE ) Nuc. Excision Repair NER protein adducts [160]
Malondialdehyde Nuc. Excision Repair NER protein adducts [161]
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Carcinogens Inhibit DNA Repair Gene Mechanism Shown Ref.
Oxidative stress
MisMatch Repair Oxidative damage to MMRproteins [162]
ERCC1 protein Oxidative attack [163]
OGG1 protein Degraded by calpain [164]
Gamma irrad. OGG1, XRCC1 mRNA reduced [165]
Benzo(a)pyrene BRCA1 miR-638 increased [166]
Methylcholanthrene/
diethylnitrosamine BRCA1, ERCC1, XRCC1, MLH1 [167]
Styrene XRCC1, OGG1, XPC mRNA reduced [168]
Aristolochic acid P53, PARP1, OGG1, ERCC1, MGMT mRNA reduced [169]
Antimony XPE mRNA reduced [170]
Nickel MGMT Promoter methylation [171]
Table 8. Examples of carcinogenic agents that cause reduced expression of DNA repair genes
16. Polyphenols can epigenetically increase expression of DNA repair
genes
Some polyphenols affect expression of many genes, including DNA repair genes, through
epigenetic alterations, as reviewed by Link et al. [172]. Examples of DNA repair genes ex‐
pression increased by epigenetic alteration are listed in Table 9.
Phytochemical Plant source Mechanism Targeted DNARepair Genes Ref.
Epigalocatechin-3-gallate Green tea Reversal of CpG islandmethylation MGMT, MLH1 [173]
Dihydrocoumarin Yellow sweet clover p53 acetylation P53 [174]
Genistein Soy Reversal of CpG islandmethylation MGMT [173]
Genistein Soy Histone acetylation P53 [175]
Table 9. Examples of phytochemicals that increase expression of DNA repair genes by an epigenetic mechanism
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17. Possible protection against cancer by phytochemicals that increase
DNA repair by unknown mechanisms
A recent review article by Collins et al. [176] summarizes some examples of micronutrients that
affect DNA repair gene expression, though by unknown mechanisms. Table 10 lists such phy‐
tochemicals, without defined mechanisms, that increase DNA repair gene expression, along
with commonly known foods that are high in those phytochemicals [177, 178, 179].
Phytochemical (test system) Examples of foods high in nutrient
Increased DNA
Repair Gene
Expression
Ref.
Ellagic acid (mice) Raspberries, pomeganate XPA, ERCC5, DNALigase 3 [180]
Silymarin (cells in vitro) Artichoke, milk thistle MGMT
[181]
Curcumin (cells in vitro) Turmeric MGMT
Chlorogenic acid (cells in vitro) Blueberries, coffee, sunflower seeds,artichoke PARP
[182]
Caffeic acid (cells in vitro) coffee, cranberry, carrot PMS2
m-coumaric acid (cells in vitro) olives (and metabolite of caffeic acid) PARP, PMS2
3-(m-hydroxyphenyl) propionic acid (cells
in vitro)
(major metabolite of caffeic acid and
degradation product of proanthocyanidins
in chocholate)
PARP, PMS2
Table 10. Examples of phytochemicals that increase expression of DNA repair genes by unknown mechanisms
Bernstein et al. [182] evaluated antioxidants based on their ability to increase DNA repair
proteins PARP-1 and Pms2 in vitro. They tested 19 anti-oxidant compounds and of these 19
compounds only chlorogenic acid and its metabolic products: chlorogenic acid, caffeic acid,
m-coumaric acid and 3-(m-hydroxyphenyl) propionic acid, increased expression of the two
tested DNA repair genes in HCT-116 cells (Table 10).
Chlorogenic acid (CGA) (high in blueberries, coffee, sunflower seeds, artichoke) [177, 183,
184] was then tested as a preventive agent in the recently devised diet-related mouse model
of colon cancer [60]. As described above in the section Exogenous DNA damaging agents in
colorectal cancer, deoxycholic acid (DCA), a DNA damaging agent, at levels present after a
high fat diet, can cause colorectal cancer. When DCA is added to the diet of wild-type mice
to raise the level of DCA in the mouse feces to the level in feces of humans on a high fat diet,
by 10 months of feeding 94% of the mice develop tumors in their colons with 56% develop‐
ing colonic adenocarcinomas [60]. This mouse model develops tumors solely in the colon,
phenotypically similar to development of colon cancer in humans. When CGA, equivalent
to 3 cups of coffee a day for humans, was added to the DCA supplemented diet it was dra‐
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matically protective against development of colon cancer, reducing incidence of colon can‐
cer significantly from 56% to 18% [60].
18. Targeting of chemotherapeutic agents to cancers deficient in DNA
repair
As discussed above, DNA repair deficiency often arises early in progression to cancer and
can give rise to genomic instability, a general feature of cancers. If cancer cells are deficient
in DNA repair they are likely to be more vulnerable than normal cells to inactivation by
DNA damaging agents. This vulnerability of cancer cells can be exploited to the benefit of
the patient. Some of the most clinically effective chemotherapeutic agents currently used in
cancer treatment are DNA damaging agents, and their therapeutic effectiveness appears to
often depend on deficient DNA repair in cancer cells.
In the next four sections we discuss repair deficiencies in cancer cells that can be effectively
targeted by DNA damaging chemotherapeutic agents. In addition, deficiency in a DNA re‐
pair pathway that arises during tumor development may make cancer cells more reliant on
a remaining reduced set of DNA repair pathways for survival. Recent studies indicate that
drugs that inhibit one of these alternative pathways in such cancers cells can be useful in
cancer therapy. Targeting cancer cells having a repair deficiency with specific DNA damag‐
ing agents, or with agents that inhibit alternative repair pathways, offers a new promising
approach for treating a variety of cancers.
19. Targeting cancers deficient in BRCA1
The BRCA1 (breast cancer 1 early onset) protein is employed in an important DNA repair
pathway, homologous recombinational repair (HRR). This pathway removes a variety of
types of DNA damages, and is the only pathway that can accurately remove double-strand
damages such as double-strand breaks and inter-strand cross-links. BRCA1 also has other
functions related to preservation of genome integrity (reviewed by Yun and Hiom [185]). In‐
dividuals with a germ-line inherited defect in the BRCA1 gene are at increased risk of breast,
ovarian and other cancers. In addition to inherited germ-line defects in BRCA1, deficiencies
in expression of this gene may arise in somatic cells either by mutation or by epimutation
during progression to sporadic (non-germline) cancer.
Patients with a variety of types of cancer are treated effectively with chemotherapeutic
agents that cause double-strand breaks (e.g. the topoisomerase inhibitor etoposide), or cause
inter-strand cross-links (e.g. the platinum compound cisplatin). These damages can cause
cancer cells to undergo apoptosis (a form of cell death). However, patients treated with
these agents often prove to be intrinsically resistant, or develop resistance during treatment.
Quinn et al. [186] demonstrated that BRCA1 expression is necessary for such resistance. This
finding suggests that BRCA1-mediated DNA repair can protect cancer cells from therapeutic
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DNA damaging drugs. Thus, although high expression of BRCA1 may be initially beneficial
to the individual by reducing the risk of developing cancer, it also may be detrimental once
cancer has developed by counteracting the therapeutic effect of DNA-damaging agents tar‐
geted to the cancer cells.
Patients  with non-small  cell  lung cancer (NSLC) are often treated with DNA cross-link‐
ing platinum therapeutic compounds such as cisplatin, carboplatin or oxaliplatin. NSCLC
is  the  leading  cause  of  cancer  deaths  worldwide,  and  almost  70%  of  patients  with
NSCLC have locally advanced or metastatic disease at diagnosis. Improved survival after
platinum-containing chemotherapy in metastatic  NSCLC correlates  with low BRCA1 ex‐
pression in the primary tumor [187, 188]. This finding indicates that low BRCA1-mediat‐
ed  DNA repair  is  detrimental  to  the  cancer  upon treatment,  and thus  beneficial  to  the
patient.  BRCA1 likely  protects  cancer  cells  by  participating  in  a  pathway  that  removes
the  potentially  lethal  DNA  cross-links  introduced  by  the  platinum  drugs.  Since  low
BRCA1 expression in the tumor appears to be beneficial to the patient, Taron et al. [187]
and  Papadek  et  al.  [188]  concluded  that  BRCA1 expression  is  potentially  an  important
tool for use in cancer management and should be assessed for predicting chemosensitivi‐
ty and tailoring chemotherapy in lung cancer.
Over 90% of ovarian cancers appear to arise sporadically in somatic cells and are associated
with BRCA1 dysfunction. Weberpals et al. [189] showed for patients having sporadic ovari‐
an cancer treated with platinum drugs, the median survival was longer for patients with
lower expression of BRCA1 vs. higher BRCA1 expression (46 vs. 33 months).
20. Targeting cancers deficient in ERCC1
ERCC1 (Excision Repair  Cross-Complementaion group 1)  is  a  key protein needed to re‐
move  platinum  adducts  and  repair  inter-  and  intra-strand  cross-links  [190].  ERCC1  di‐
merizes with XPF (xeroderma pigmentosum complementation group F) protein to form a
complex  that  can  excise  damaged  DNA.  Over-expression  of  ERCC1  is  associated  with
cellular  resistance  to  platinum  compounds,  whereas  ERCC1  down-regulation  sensitizes
cells to cisplatin [191, 192].
Cisplatin has made a major impact in the chemotherapeutic treatment of testicular cancer.
Over 90% of patients with newly diagnosed testicular germ cell cancer, and 70 to 80% of pa‐
tients with metastatic testicular cancer, can be cured using cisplatin based combination che‐
motherapy [193]. Hypersensitivity of testicular cancer to cisplatin appears to be due to low
levels of the three NER proteins ERCC1, XPF and XPA [194].
Simon et al. [195] evaluated ERCC1 mRNA expression in lung tumors as a predictor of sur‐
vival of NSCLC patients. They found that patients with relatively low ERCC1 mRNA ex‐
pression had poor overall survival. This finding suggests that low ERCC1-mediated DNA
repair allows DNA damages to persist and give rise to carcinogenic mutations. However,
they also noted that those NSCLC tumors with relatively low ERCC1 expression responded
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better to platinum based therapy. Lord et al. [196] found that low ERCC1 mRNA expression
in the primary tumor correlates with prolonged survival after cisplatin plus gemitabine che‐
motherapy in NSCLC. Median overall survival with low ERCC1 expression tumors was 61.6
weeks compared to 20.4 weeks for patients with high expression tumors.
Zhou et al. [197] reported that a particular genetic polymorphism that alters ERCC1 mRNA
level predicts overall survival in advanced NSCLC patients treated with platinum based
chemotherapy. Olaussen et al. [198] found that patients with completely resected NSCLC tu‐
mors that were ERCC1-negative benefited from adjuvant cisplatin-based chemotherapy,
whereas patients with ERCC1-positive tumors did not benefit. They suggested that determi‐
nation of ERCC1 expression in NSCLC cells before chemotherapy can make a contribution
as an independent predictor of the effect of adjuvant chemotherapy. Papadaki et al. [188]
found that ERCC1 mRNA level in the primary tumor of patients with metastatic NSCLC
could predict the effectiveness of cisplatin based chemotherapy. Low ERCC1 mRNA level
was significantly associated with higher response rate, longer median progression-free sur‐
vival and median overall survival. Leng et al. [199] found that patients with ERCC1 negative
expression had a longer progression free survival and overall survival than ERCC1 positive
patients after receiving platinum based adjuvant therapy. Thus ERCC1 mRNA level, like
BRCA1 mRNA level (discussed above), in the primary tumor at the time of diagnosis could
be used to predict platinum sensitivity of NSCLC.
ERCC1 expression also  appears  to  have predictive  significance for  ovarian cancer.  Dab‐
holkar  et  al.  [200]  found in  ovarian tumor tissues  that  ERCC1  mRNA expression levels
were higher in patients who were resistant to platinum based therapy than in those pa‐
tients who responded to such therapy. Kang et al.  [201] observed that a particular poly‐
morphism of the ERCC1 gene sequence was associated with clinical outcome of platinum
based chemotherapy in patients with ovarian cancer. Weberpals et al.  [189] also showed
for ovarian cancer patients that higher ERCC1 mRNA level,  alone, or especially in com‐
bination with higher BRCA1  mRNA level in the tumor, predicted shorter overall patient
survival after platinum therapy.
ERCC1 protein expression is often reduced within colon cancers and in a field defect sur‐
rounding these cancers [112]. For metastatic colorectal cancer patients receiving combination
oxaliplatin and fluorouracil chemotherapy, lower ERCC1 mRNA expression in the tumor
predicts longer survival [202]. Viguier et al. [203] found that a particular ERCC1 genetic
polymorphism predicts a better tumor response to oxaliplatin/5-fluorouracil combination
chemotherapy in patients with metastatic colorectal cancer.
Low ERCC1 mRNA levels also predict better response and survival for gastric cancer pa‐
tients [204] and bladder cancer patients [205] receiving cisplatin-based chemotherapy.
Thus numerous studies involving cancer of the testis, lung, ovary, colon, stomach and blad‐
der indicated that platinum based chemotherapy can enhance patient outcome when target‐
ed specifically to tumors with low ERCC1 expression. Such tumors have diminished ability
to repair the DNA damages, particularly the cross-links, induced in the tumors by the plati‐
num compound.
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21. Targeting cancers deficient in MGMT
Alkylating agents, including chloroethylnitrosoureas, procarbazine and temozolomide, are
commonly used to treat malignant brain tumors. These agents cause DNA damage by add‐
ing alkyl groups to DNA. Such damages may then be repaired or, if unrepaired, trigger cell
death. As an example, temozolomide methylates DNA at several sites generating mainly N7-
methylguanine and N3-methyladenine adducts, which constitute nearly 90% of the total
methylation events. However these adducts are efficiently removed and accurately replaced
by the base excision repair pathway, and thus have low cytotoxic potential. About 5 to 10%
of the methylation events caused by temozolomide produce O6-methylguanine which is cy‐
totoxic, and this adduct accounts for the beneficial therapeutic effect of temozolomide and
other alkylating agents on malignant brain tumors.
O6-methylguanine  methyltransferase  (MGMT)  is  a  DNA  repair  enzyme  that  rapidly  re‐
verses  alkylation  (including  methylation)  at  the  O6  position  of  guanine,  thus  neutraliz‐
ing  the  cytotoxic  effects  of  chemotherapeutic  alkylating  agents  such  as  temozolomide.
High  MGMT activity  in  tumor  tissue  is  associated  with  resistance  to  alkylating  agents.
MGMT  activity  is  controlled  by  a  promoter  sequence,  and  methylation  of  the  CpG  is‐
land in the promoter silences the gene in cancer cells,  so that these cells no longer pro‐
duce  MGMT.  In  addition,  as  described  above,  an  increased  level  of  miR-181d  can  also
decrease  MGMT  expression  and  help  the  ability  of  temozolomide  to  give  a  beneficial
therapeutic effect [78].
Esteller  et  al.  [206]  showed  that  methylation  of  the  MGMT  promoter  increases  the  re‐
sponsiveness of  the gliomas (brain tumors)  to  chemotherapeutic  alkylating agents,  lead‐
ing to regression of  the tumors and prolonged overall  and disease free survival.  Paz et
al.  [207] showed that hypermethylation of CpG islands within the promoter sequence of
the MGMT  gene predicts a better clinical response to temozolomide in primary gliomas.
They  considered  that  their  results  might  open  up  possibilities  for  more  customized
treatments  of  human  brain  tumors.  Hegi  et  al.  [208]  demonstrated  a  significantly  im‐
proved  clinical  outcome  in  patients  with  malignant  glioma  who  had  a  methylated
MGMT  promoter and were treated with temozolomide.  The 18-month survival rate was
62% among patients with a methylated MGMT  promoter compared with only 8% in the
absence  of  promoter  methylation.  Hegi  et  al.  [209]  reviewed  further  evidence  that
MGMT  promoter  methylation  is  associated  with  improved  progression-free  and  overall
survival  in  malignant  glioma  patients  treated  with  alkylating  agents.  They  also  dis‐
cussed  strategies  to  overcome  MGMT-mediated  chemoresistance  that  are  currently  un‐
der  investigation.  Upon  reviewing  the  relevant  evidence,  Weller  et  al.  [210]  concluded
that  MGMT  promoter  methylation is  the  key mechanism of  MGMT  gene silencing,  and
could  be  used as  a  biomarker  for  predicting  a  favorable  outcome in  patients  with  ma‐
lignant  glioma who are  exposed to  alkylating  chemotherapy.  They  considered  that  this
biomarker is on the verge of entering clinical decision-making.
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22. Targeting cancers with a repair deficiency using a PARP inhibitor;
synthetic lethality
If a tumor is deficient in an essential protein component of a DNA repair pathway, the can‐
cer cells would likely be more reliant on remaining DNA repair pathways for survival.
Drugs that inhibit one of these alternative pathways, in principle, might prove to be useful
in cancer therapy by selectively killing the cancer cells. An example of such an approach is
the use of poly(ADP-ribose) polymerase [PARP] inhibitors against tumors that are deficient
in BRCA1 or BRCA2 [211]. This approach has provided proof-of-concept for an anticancer
strategy termed “synthetic lethality.” By this strategy the inhibition of a particular repair
pathway in cancer cells that are already deficient in another repair pathway preferentially
induces greater toxicity in repair deficient cancer cells than in normal non-cancer cells. Cur‐
rent research guided by this strategy is directed at finding new agents that inactivate protein
components of major repair pathways, and thus could be targeted against cancers that are
already deficient in another repair pathway [212].
A germ-line  mutation in  one BRCA1  or  BRCA2  allele  substantially  increases  the  risk  of
developing several  cancers,  including breast,  ovarian,  and prostate  cancer.  Diploid  cells
heterozygous for  either  a  BRCA1  or  a  BRCA2  mutant  allele  may lose  expression of  the
remaining  wild-type  allele,  resulting  in  deficient  homologous  recombinational  repair.
This  loss  causes  an  increase  in  unrepaired  DSBs  that  can  lead  to  mutations  (through
compensatory inaccurate repair)  and chromosomal aberrations that  drive carcinogenesis.
Inactivation of the wild-type allele in the cell  lineage leading to the tumor is thought to
be  an  obligate  step  in  this  carcinogenesis  pathway,  a  step  that  does  not  occur  in  the
normal non-cancer tissues of the patient.
The deficiency in homologous recombinational repair is thus specific to the tumor, and can
be exploited by employing PARP inhibitors. Ordinarily, single-strand breaks (SSBs), as dis‐
tinct from DSBs, are repaired by the base excision repair pathway, in which the enzyme
PARP1 plays a key role. The inhibition of PARP1 leads to the accumulation of DNA SSBs.
Unrepaired SSBs can give rise to DSBs at replication forks during DNA replication. Thus
PARP inhibition in tumor cells with deficient homologous recombinational repair (because
of the absence of BRCA1 or BRCA2) generates unrepaired SSBs that are likely to cause an
overwhelming accumulation of DSBs leading to tumor cell death. In contrast, the normal tis‐
sues of a patient consists of cells that are heterozygous for a BRCA1 or BRCA2 mutant allele
and therefore retain homologous recombinational repair function, and have a sensitivity to
PARP inhibitors similar to that of wild-type cells. Thus PARP inhibition induces selective tu‐
mor cell killing while sparing normal cells.
Fong et  al.  [213]  conducted a preliminary clinical  evaluation of  the oral  PARP inhibitor
olaparib.  They observed that 63% of patients carrying BRCA1  or  BRCA2  mutations who
had ovarian, breast or prostate cancer had a clinical benefit  from treatment with olapar‐
ib with few adverse side effects.  This is an example of the concept of “synthetic lethali‐
ty”  which  occurs  when  there  is  a  potent  lethal  synergy  between  two  otherwise  non-
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lethal events.  The two events in this case are (1) a specific PARP inhibitor blocks repair
of SSBs causing an increase in SSBs leading to an increase in DSBs; and (2) a tumor re‐
stricted genetic  loss of  function or  homologous recombinational  repair  that  is  ordinarily
needed to accurately repair these DSBs.
A subsequent trial of olaparib in BRCA mutation-associated breast cancer demonstrated ob‐
jective positive response rates of 41%, again with limited toxicity [214]. About 10% of wom‐
en with ovarian cancer carry a BRCA1 or BRCA2 mutant allele. Audeh et al. [215] showed
that the oral PARP inhibitor olaparib has antitumor activity in women carriers of BRCA1 or
BRCA2 alleles who have ovarian cancer. The objective positive response rate was 33%.
23. Overview of the role of DNA damage and repair in carcinogenesis
In this  section we present a brief  overview of the relationship of  DNA damage and re‐
pair  to carcinogenesis,  and the implications of  this  relationship for  strategies  of  preven‐
tion and therapy, emphasizing the evidence reviewed above. Carcinogenesis is generally
viewed as a Darwinian process that occurs in a somatic cell lineage by mutation or epi‐
mutation  and  natural  selection.  Natural  selection  operates  on  the  basis  of  the  adaptive
benefit  to individual cells  in the lineage of more rapid cell  division or higher resistance
to cell death (apoptosis) than occurs in neighboring cells. Most of the random mutations
and  epimutations  that  arise  during  progression  to  cancer  are  likely  to  be  disadvanta‐
geous  or  neutral  from the  prospective  of  the  emerging  cancerous  cells,  and  only  those
that promote more rapid overall growth are advantageous. The cell lineage that ultimate‐
ly  becomes  a  cancer  probably  passes  through  a  series  of  evolutionary  pre-cancerous
stages involving sequential  rounds of  mutation/epimutation and selection [216].  The ini‐
tial  stage  is  probably  a  lineage  of  cells  with  a  small  selective  advantage  that  forms  an
early  field within a  tissue.  Within this  defective  field successive  mutation and selection
events occur which finally give rise to an invasive and then metastatic cell lineage. Dur‐
ing this process the cell  lineage acquires the hallmarks of cancer (summarized by Hana‐
han  and  Weinberg  [217]).  These  include:  sustaining  proliferative  signaling,  evading
growth suppressors, resisting cell death, enabling replicative immortality, inducing angio‐
genesis, reprogramming energy metabolism, and evading immune destruction.
Mutations arise from unrepaired DNA damages, either by translesion synthesis during
DNA replication or by inaccurate repair of DNA damages, as in the inaccurate process of
non-homologous end joining of double-strand breaks. Mutations may also arise by sponta‐
neous replication errors without the intervention of DNA damage, but this source of muta‐
tion is likely less frequent than mutations caused by DNA damage. The primary cause(s) of
epimutations (such as CpG island methylations) are not well understood, but evidence sug‐
gests that epimutations arise during the repair processes that remove DNA damages. The
sources of DNA damage underlying carcinogenesis can be extrinsic or intrinsic. Epidemio‐
logic evidence suggests that a large proportion of the DNA damages contributing to cancer
arise from extrinsic stressful conditions, including such factors as smoking, high fat diet, cer‐
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tain infections and UV light exposure. The possible contribution from intrinsic causes, such
as free radical production during normal metabolism, have not been assessed. A pervasive
characteristic of human tumors is genomic instability [217]. A likely major source of this in‐
stability is loss of DNA repair capability. Germ line mutations in DNA repair genes general‐
ly lead to syndromes characterized by a greatly increased risk of cancer. The majority of
cancers arise sporadically, i.e. are not primarily due to germ line mutations. A frequent char‐
acteristic of sporadic cancers is loss of expression of one or more DNA repair proteins
through epigenetic silencing. The several different DNA repair pathways that occur in mam‐
malian cells each specialize in removing different types of damage, but they are also partial‐
ly overlapping. Thus reduction of a particular repair pathway may have different
carcinogenic consequences from loss of another repair pathway [218]. However, the deleteri‐
ous effect of loss of one pathway may be partially ameliorated by another functioning path‐
way.
This general view of the role of DNA damage and repair in carcinogenesis has implications
for the prevention and treatment of cancer. Cancer incidence could be substantially reduced
by a general avoidance of the known sources of DNA damage such as smoking. In addition
to avoiding DNA damage, it should also be beneficial to increase DNA repair, or at least to
avoid extrinsic factors that decrease repair. The factors affecting repair capability are less
well studied than those causing DNA damage, but several are known, and a significant ben‐
efit may be derived from considering such factors as well.
The finding that DNA repair deficiency is a common feature of cancers, and is perhaps the
underlying cause of the genetic instability of cancers, has implications for therapy. If a can‐
cer is composed of cells deficient in DNA repair, it is, in principle, vulnerable to agents that
cause DNA damage. Thus a chemotherapeutic DNA damaging agent can be targeted to can‐
cers that lack the capability to repair the particular type of DNA damage caused by the
agent. This can lead to a level of DNA damages that overwhelms the defenses of the cancer
cells and causes their death. Non-cancerous cells with normal repair would not be targeted.
Thus the toxicity of such DNA damaging agents to the treated patient would be limited. A
dramatic example of such targeted therapy is the high cure rate of testicular cancer due to a
defect in the ability of the cancer cells to repair DNA inter-strand cross-links, and the use of
cross-linking platinum compounds to kill such cells.
Another strategy, which is currently the basis for numerous ongoing clinical trials, involves
synthetic lethality. By this strategy cancers that are deficient in one DNA repair pathway can
be made more vulnerable to DNA damage by treatment with agents that inhibit an addi‐
tional repair pathway. Promising clinical results, so far, have been obtained in the treatment
of patients with breast and ovarian cancer due to an inherited genetic defect in the homolo‐
gous recombinational repair pathway. Such cancers are deficient in the ability to repair dou‐
ble-strand breaks. Treatment of these cancers with an agent that interferes with another
pathway that ordinarily repairs single-strand breaks allows such breaks to accumulate and
to be converted to double-strand breaks during DNA replication. The increase in double-
strand breaks appears to overwhelm the cancer cells, while sparing normal cells, thus pro‐
viding positive clinical benefit to the patient without much toxicity.
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